Biocon has reported results for first quarter ended June 30, 2021.
The company has reported a fall of 65.68% in its net profit at Rs 29.10 crore for the quarter under review as compared to Rs 84.80 crore for the same quarter in the previous year. Total income of the company decreased by 22.42% at Rs 431.90 crore for Q1FY22 as compared Rs 556.70 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 43.51% in its net profit attributed to the shareholders at Rs 84.40 crore for the quarter under review as compared to Rs 149.40 crore for the same quarter in the previous year. However, total income of the company increased by 5.59% at Rs 1807.80 crore for Q1FY22 as compared Rs 1712.10 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: